Translational strategy using multiple nuclear imaging biomarkers to evaluate target engagement and early therapeutic efficacy of SAR439859, a novel selective estrogen receptor degrader
Purpose Preclinical in vivo nuclear imaging of mice offers an enabling perspective to evaluate drug efficacy at optimal dose and schedule. In this study, we interrogated sufficient estrogen receptor occupancy and degradation for the selective estrogen receptor degrader (SERD) compound SAR439859 usin...
Saved in:
Published in | EJNMMI research Vol. 10; no. 1; p. 70 |
---|---|
Main Authors | , , , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Berlin/Heidelberg
Springer Berlin Heidelberg
29.06.2020
Springer Nature B.V SpringerOpen |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Purpose
Preclinical in vivo nuclear imaging of mice offers an enabling perspective to evaluate drug efficacy at optimal dose and schedule. In this study, we interrogated sufficient estrogen receptor occupancy and degradation for the selective estrogen receptor degrader (SERD) compound SAR439859 using molecular imaging and histological techniques.
Material and methods
[
18
F]FluoroEstradiol positron emission tomography (FES-PET), [
18
F]FluoroDeoxyGlucose (FDG) PET, and [
18
F]FluoroThymidine (FLT) PET were investigated as early pharmacodynamic, tumor metabolism, and tumor proliferation imaging biomarkers, respectively, in mice bearing subcutaneous MCF7-Y537S mutant ERα+ breast cancer model treated with the SERD agent SAR439859. ER expression and proliferation index Ki-67 were assessed by immunohistochemistry (IHC). The combination of palbociclib CDK 4/6 inhibitor with SAR439859 was tested for its potential synergistic effect on anti-tumor activity.
Results
After repeated SAR439859 oral administration over 4 days, FES tumoral uptake (SUVmean) decreases compared to baseline by 35, 57, and 55% for the 25 mg/kg qd, 12.5 mg/kg bid and 5 mg/kg bid treatment groups, respectively. FES tumor uptake following SAR439859 treatment at different doses correlates with immunohistochemical scoring for ERα expression. No significant difference in FDG uptake is observed after SAR439859 treatments over 3 days. FLT accumulation in tumor is significantly decreased when palbociclib is combined to SAR439859 (− 64%) but not different from the group dosed with palbociclib alone (− 46%). The impact on proliferation is corroborated by Ki-67 IHC data for both groups of treatment.
Conclusions
In our preclinical studies, dose-dependent inhibition of FES tumoral uptake confirmed target engagement of SAR439859 to ERα. FES-PET thus appears as a relevant imaging biomarker for measuring non-invasively the impact of SAR439859 on tumor estrogen receptor occupancy. This study further validates the use of FLT-PET to directly visualize the anti-proliferative tumor effect of the palbociclib CDK 4/6 inhibitor alone and in combination with SAR439859. |
---|---|
AbstractList | PurposePreclinical in vivo nuclear imaging of mice offers an enabling perspective to evaluate drug efficacy at optimal dose and schedule. In this study, we interrogated sufficient estrogen receptor occupancy and degradation for the selective estrogen receptor degrader (SERD) compound SAR439859 using molecular imaging and histological techniques.Material and methods[18F]FluoroEstradiol positron emission tomography (FES-PET), [18F]FluoroDeoxyGlucose (FDG) PET, and [18F]FluoroThymidine (FLT) PET were investigated as early pharmacodynamic, tumor metabolism, and tumor proliferation imaging biomarkers, respectively, in mice bearing subcutaneous MCF7-Y537S mutant ERα+ breast cancer model treated with the SERD agent SAR439859. ER expression and proliferation index Ki-67 were assessed by immunohistochemistry (IHC). The combination of palbociclib CDK 4/6 inhibitor with SAR439859 was tested for its potential synergistic effect on anti-tumor activity.ResultsAfter repeated SAR439859 oral administration over 4 days, FES tumoral uptake (SUVmean) decreases compared to baseline by 35, 57, and 55% for the 25 mg/kg qd, 12.5 mg/kg bid and 5 mg/kg bid treatment groups, respectively. FES tumor uptake following SAR439859 treatment at different doses correlates with immunohistochemical scoring for ERα expression. No significant difference in FDG uptake is observed after SAR439859 treatments over 3 days. FLT accumulation in tumor is significantly decreased when palbociclib is combined to SAR439859 (− 64%) but not different from the group dosed with palbociclib alone (− 46%). The impact on proliferation is corroborated by Ki-67 IHC data for both groups of treatment.ConclusionsIn our preclinical studies, dose-dependent inhibition of FES tumoral uptake confirmed target engagement of SAR439859 to ERα. FES-PET thus appears as a relevant imaging biomarker for measuring non-invasively the impact of SAR439859 on tumor estrogen receptor occupancy. This study further validates the use of FLT-PET to directly visualize the anti-proliferative tumor effect of the palbociclib CDK 4/6 inhibitor alone and in combination with SAR439859. Purpose Preclinical in vivo nuclear imaging of mice offers an enabling perspective to evaluate drug efficacy at optimal dose and schedule. In this study, we interrogated sufficient estrogen receptor occupancy and degradation for the selective estrogen receptor degrader (SERD) compound SAR439859 using molecular imaging and histological techniques. Material and methods [ 18 F]FluoroEstradiol positron emission tomography (FES-PET), [ 18 F]FluoroDeoxyGlucose (FDG) PET, and [ 18 F]FluoroThymidine (FLT) PET were investigated as early pharmacodynamic, tumor metabolism, and tumor proliferation imaging biomarkers, respectively, in mice bearing subcutaneous MCF7-Y537S mutant ERα+ breast cancer model treated with the SERD agent SAR439859. ER expression and proliferation index Ki-67 were assessed by immunohistochemistry (IHC). The combination of palbociclib CDK 4/6 inhibitor with SAR439859 was tested for its potential synergistic effect on anti-tumor activity. Results After repeated SAR439859 oral administration over 4 days, FES tumoral uptake (SUVmean) decreases compared to baseline by 35, 57, and 55% for the 25 mg/kg qd, 12.5 mg/kg bid and 5 mg/kg bid treatment groups, respectively. FES tumor uptake following SAR439859 treatment at different doses correlates with immunohistochemical scoring for ERα expression. No significant difference in FDG uptake is observed after SAR439859 treatments over 3 days. FLT accumulation in tumor is significantly decreased when palbociclib is combined to SAR439859 (− 64%) but not different from the group dosed with palbociclib alone (− 46%). The impact on proliferation is corroborated by Ki-67 IHC data for both groups of treatment. Conclusions In our preclinical studies, dose-dependent inhibition of FES tumoral uptake confirmed target engagement of SAR439859 to ERα. FES-PET thus appears as a relevant imaging biomarker for measuring non-invasively the impact of SAR439859 on tumor estrogen receptor occupancy. This study further validates the use of FLT-PET to directly visualize the anti-proliferative tumor effect of the palbociclib CDK 4/6 inhibitor alone and in combination with SAR439859. Abstract Purpose Preclinical in vivo nuclear imaging of mice offers an enabling perspective to evaluate drug efficacy at optimal dose and schedule. In this study, we interrogated sufficient estrogen receptor occupancy and degradation for the selective estrogen receptor degrader (SERD) compound SAR439859 using molecular imaging and histological techniques. Material and methods [ 18 F]FluoroEstradiol positron emission tomography (FES-PET), [ 18 F]FluoroDeoxyGlucose (FDG) PET, and [ 18 F]FluoroThymidine (FLT) PET were investigated as early pharmacodynamic, tumor metabolism, and tumor proliferation imaging biomarkers, respectively, in mice bearing subcutaneous MCF7-Y537S mutant ERα+ breast cancer model treated with the SERD agent SAR439859. ER expression and proliferation index Ki-67 were assessed by immunohistochemistry (IHC). The combination of palbociclib CDK 4/6 inhibitor with SAR439859 was tested for its potential synergistic effect on anti-tumor activity. Results After repeated SAR439859 oral administration over 4 days, FES tumoral uptake (SUVmean) decreases compared to baseline by 35, 57, and 55% for the 25 mg/kg qd, 12.5 mg/kg bid and 5 mg/kg bid treatment groups, respectively. FES tumor uptake following SAR439859 treatment at different doses correlates with immunohistochemical scoring for ERα expression. No significant difference in FDG uptake is observed after SAR439859 treatments over 3 days. FLT accumulation in tumor is significantly decreased when palbociclib is combined to SAR439859 (− 64%) but not different from the group dosed with palbociclib alone (− 46%). The impact on proliferation is corroborated by Ki-67 IHC data for both groups of treatment. Conclusions In our preclinical studies, dose-dependent inhibition of FES tumoral uptake confirmed target engagement of SAR439859 to ERα. FES-PET thus appears as a relevant imaging biomarker for measuring non-invasively the impact of SAR439859 on tumor estrogen receptor occupancy. This study further validates the use of FLT-PET to directly visualize the anti-proliferative tumor effect of the palbociclib CDK 4/6 inhibitor alone and in combination with SAR439859. PURPOSEPreclinical in vivo nuclear imaging of mice offers an enabling perspective to evaluate drug efficacy at optimal dose and schedule. In this study, we interrogated sufficient estrogen receptor occupancy and degradation for the selective estrogen receptor degrader (SERD) compound SAR439859 using molecular imaging and histological techniques. MATERIAL AND METHODS[18F]FluoroEstradiol positron emission tomography (FES-PET), [18F]FluoroDeoxyGlucose (FDG) PET, and [18F]FluoroThymidine (FLT) PET were investigated as early pharmacodynamic, tumor metabolism, and tumor proliferation imaging biomarkers, respectively, in mice bearing subcutaneous MCF7-Y537S mutant ERα+ breast cancer model treated with the SERD agent SAR439859. ER expression and proliferation index Ki-67 were assessed by immunohistochemistry (IHC). The combination of palbociclib CDK 4/6 inhibitor with SAR439859 was tested for its potential synergistic effect on anti-tumor activity. RESULTSAfter repeated SAR439859 oral administration over 4 days, FES tumoral uptake (SUVmean) decreases compared to baseline by 35, 57, and 55% for the 25 mg/kg qd, 12.5 mg/kg bid and 5 mg/kg bid treatment groups, respectively. FES tumor uptake following SAR439859 treatment at different doses correlates with immunohistochemical scoring for ERα expression. No significant difference in FDG uptake is observed after SAR439859 treatments over 3 days. FLT accumulation in tumor is significantly decreased when palbociclib is combined to SAR439859 (- 64%) but not different from the group dosed with palbociclib alone (- 46%). The impact on proliferation is corroborated by Ki-67 IHC data for both groups of treatment. CONCLUSIONSIn our preclinical studies, dose-dependent inhibition of FES tumoral uptake confirmed target engagement of SAR439859 to ERα. FES-PET thus appears as a relevant imaging biomarker for measuring non-invasively the impact of SAR439859 on tumor estrogen receptor occupancy. This study further validates the use of FLT-PET to directly visualize the anti-proliferative tumor effect of the palbociclib CDK 4/6 inhibitor alone and in combination with SAR439859. Abstract Purpose Preclinical in vivo nuclear imaging of mice offers an enabling perspective to evaluate drug efficacy at optimal dose and schedule. In this study, we interrogated sufficient estrogen receptor occupancy and degradation for the selective estrogen receptor degrader (SERD) compound SAR439859 using molecular imaging and histological techniques. Material and methods [18F]FluoroEstradiol positron emission tomography (FES-PET), [18F]FluoroDeoxyGlucose (FDG) PET, and [18F]FluoroThymidine (FLT) PET were investigated as early pharmacodynamic, tumor metabolism, and tumor proliferation imaging biomarkers, respectively, in mice bearing subcutaneous MCF7-Y537S mutant ERα+ breast cancer model treated with the SERD agent SAR439859. ER expression and proliferation index Ki-67 were assessed by immunohistochemistry (IHC). The combination of palbociclib CDK 4/6 inhibitor with SAR439859 was tested for its potential synergistic effect on anti-tumor activity. Results After repeated SAR439859 oral administration over 4 days, FES tumoral uptake (SUVmean) decreases compared to baseline by 35, 57, and 55% for the 25 mg/kg qd, 12.5 mg/kg bid and 5 mg/kg bid treatment groups, respectively. FES tumor uptake following SAR439859 treatment at different doses correlates with immunohistochemical scoring for ERα expression. No significant difference in FDG uptake is observed after SAR439859 treatments over 3 days. FLT accumulation in tumor is significantly decreased when palbociclib is combined to SAR439859 (− 64%) but not different from the group dosed with palbociclib alone (− 46%). The impact on proliferation is corroborated by Ki-67 IHC data for both groups of treatment. Conclusions In our preclinical studies, dose-dependent inhibition of FES tumoral uptake confirmed target engagement of SAR439859 to ERα. FES-PET thus appears as a relevant imaging biomarker for measuring non-invasively the impact of SAR439859 on tumor estrogen receptor occupancy. This study further validates the use of FLT-PET to directly visualize the anti-proliferative tumor effect of the palbociclib CDK 4/6 inhibitor alone and in combination with SAR439859. |
ArticleNumber | 70 |
Author | Shomali, Maysoun Caron, Anne Andrieu, Laurent d’Heilly, Sébastien Rao, Srinivas Besret, Laurent Bluet, Guillaume Roy, Sébastien Ming, Jeffrey Aubert, Cathy Le-Gall, Françoise Vincent, Sylvie Jouannot, Erwan Carrez, Chantal Gruss-Leleu, Florence Bouaboula, Monsif Voland, Carole |
Author_xml | – sequence: 1 givenname: Laurent surname: Besret fullname: Besret, Laurent email: laurent.besret@sanofi.com organization: Sanofi Research and Development France – sequence: 2 givenname: Sébastien surname: d’Heilly fullname: d’Heilly, Sébastien organization: Sanofi Research and Development France – sequence: 3 givenname: Cathy surname: Aubert fullname: Aubert, Cathy organization: Sanofi Research and Development France – sequence: 4 givenname: Guillaume surname: Bluet fullname: Bluet, Guillaume organization: Sanofi Research and Development France – sequence: 5 givenname: Florence surname: Gruss-Leleu fullname: Gruss-Leleu, Florence organization: Sanofi Research and Development France – sequence: 6 givenname: Françoise surname: Le-Gall fullname: Le-Gall, Françoise organization: Sanofi Research and Development France – sequence: 7 givenname: Anne surname: Caron fullname: Caron, Anne organization: Sanofi Research and Development France – sequence: 8 givenname: Laurent surname: Andrieu fullname: Andrieu, Laurent organization: Sanofi Research and Development France – sequence: 9 givenname: Sylvie surname: Vincent fullname: Vincent, Sylvie organization: Present address: Takeda Pharmaceuticals – sequence: 10 givenname: Maysoun surname: Shomali fullname: Shomali, Maysoun organization: Sanofi Research and Development USA – sequence: 11 givenname: Monsif surname: Bouaboula fullname: Bouaboula, Monsif organization: Sanofi Research and Development USA – sequence: 12 givenname: Carole surname: Voland fullname: Voland, Carole organization: Sanofi Research and Development France – sequence: 13 givenname: Jeffrey surname: Ming fullname: Ming, Jeffrey organization: Sanofi Research and Development USA – sequence: 14 givenname: Sébastien surname: Roy fullname: Roy, Sébastien organization: Sanofi Research and Development France – sequence: 15 givenname: Srinivas surname: Rao fullname: Rao, Srinivas organization: Sanofi Research and Development USA – sequence: 16 givenname: Chantal surname: Carrez fullname: Carrez, Chantal organization: Sanofi Research and Development France – sequence: 17 givenname: Erwan surname: Jouannot fullname: Jouannot, Erwan organization: Sanofi Research and Development France |
BookMark | eNp9Uk1v1DAQjVARLaV_gJMlLhwI-CNOnAtSVUGpVAkJisTNmjiTNItjL7az1f4zfl69uxVQDljyhzzvvXkez_PiyHmHRfGS0beMqfpdZEJKWlKeJ62rurx7Upxw1rIyL9-P_jofF2cxrmgekslWqGfFseA1ZU3DT4pfNwFctJAm78CSmAIkHLdkiZMbybzYNK0tErcYixDINMO4C3STnyH8wBBJ8gQ3YJfMIwnCiImgG2HEGV0i4HqSiXZL0i0GWOOSJkNwGCYDZkv8QL6ef6lEq2T7hgBxfoPZBVo0adogwWzIj-hIQIPr5APpcQzQY3hRPB3ARjx72E-Lbx8_3Fx8Kq8_X15dnF-XRqoqlbITHAU1tWw6xTlloukVBdr3quOCMSMbRVs69LTnpjUMW0apwVrVqpNGMHFaXB10ew8rvQ65AmGrPUx6f-HDqCHkN1nUFWtBVgYwp6naZuhy2oHTgWfVmvdV1np_0Fov3Yy9yQUKYB-JPo646VaPfqMbwauq3gm8fhAI_ueSi6PnKRq0Fhz6JWqeLdBWcbnz_eof6MovIf_xHqUqSduqzih-QJngYww4_DbDqN71mT70mc59pvd9pu8ySRxIMYPdiOGP9H9Y93W32bk |
CitedBy_id | crossref_primary_10_1039_D0RE00442A crossref_primary_10_4236_jbm_2024_121010 crossref_primary_10_1007_s10555_022_10066_y crossref_primary_10_1007_s12282_023_01443_8 crossref_primary_10_1016_j_ejphar_2024_176424 crossref_primary_10_1038_s41467_022_31668_8 crossref_primary_10_1158_1078_0432_CCR_23_0011 |
Cites_doi | 10.2174/1874471009666161019144950 10.2967/jnumed.116.178368 10.1200/JCO.2015.61.5831 10.1038/s41598-017-06903-8 10.1158/1078-0432.CCR-14-1178 10.1016/j.mce.2015.09.035 10.1016/j.ejca.2012.05.001 10.1016/S1470-2045(13)70292-4 10.1200/JCO.2001.19.11.2797 10.1186/bcr1639 10.2967/jnumed.116.175596 10.1007/s11307-005-0029-9 10.1038/nrd1007 10.1158/1078-0432.CCR-16-2197 10.1021/acs.jmedchem.9b01293 10.1016/j.molonc.2012.02.003 10.1021/acs.jmedchem.5b00760 10.1021/acs.jmedchem.6b01355 10.1053/j.semnuclmed.2015.09.002 10.1158/1078-0432.CCR-16-0362 10.1016/j.cpet.2018.02.005 10.1158/1078-0432.CCR-18-2769 10.1038/ng.2822 10.1111/j.1365-2125.2011.04085.x 10.1634/theoncologist.2014-0443 10.1158/1078-0432.CCR-15-0360 10.1093/ajcp/aqy028 10.1200/JCO.2005.04.3810 10.1007/s10549-017-4385-3 10.1016/S1470-2045(15)00613-0 10.1158/1538-7445.SABCS16-P3-04-05 10.2967/jnumed.115.157974 10.1158/1538-7445.AM2018-943 |
ContentType | Journal Article |
Copyright | The Author(s) 2020 The Author(s) 2020. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
Copyright_xml | – notice: The Author(s) 2020 – notice: The Author(s) 2020. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
DBID | C6C AAYXX CITATION 3V. 7X7 7XB 8AO 8FE 8FG 8FI 8FJ 8FK ABUWG AFKRA ARAPS AZQEC BENPR BGLVJ CCPQU DWQXO FYUFA GHDGH HCIFZ K9. M0S P5Z P62 PIMPY PQEST PQQKQ PQUKI PRINS 7X8 5PM DOA |
DOI | 10.1186/s13550-020-00646-w |
DatabaseName | Springer_OA刊 CrossRef ProQuest Central (Corporate) ProQuest_Health & Medical Collection ProQuest Central (purchase pre-March 2016) ProQuest Pharma Collection ProQuest SciTech Collection ProQuest Technology Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central Advanced Technologies & Aerospace Database (1962 - current) ProQuest Central Essentials AUTh Library subscriptions: ProQuest Central Technology Collection ProQuest One Community College ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) SciTech Premium Collection (Proquest) (PQ_SDU_P3) ProQuest Health & Medical Complete (Alumni) Health & Medical Collection (Alumni Edition) ProQuest advanced technologies & aerospace journals ProQuest Advanced Technologies & Aerospace Collection ProQuest - Publicly Available Content Database ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
DatabaseTitle | CrossRef Publicly Available Content Database Technology Collection ProQuest Advanced Technologies & Aerospace Collection ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College ProQuest Pharma Collection ProQuest Central China ProQuest Central Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Advanced Technologies & Aerospace Collection ProQuest One Academic Eastern Edition ProQuest Hospital Collection ProQuest Technology Collection Health Research Premium Collection (Alumni) ProQuest SciTech Collection ProQuest Hospital Collection (Alumni) Advanced Technologies & Aerospace Database ProQuest Health & Medical Complete ProQuest One Academic UKI Edition ProQuest One Academic ProQuest Central (Alumni) MEDLINE - Academic |
DatabaseTitleList | Publicly Available Content Database CrossRef MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: C6C name: Springer_OA刊 url: http://www.springeropen.com/ sourceTypes: Publisher – sequence: 2 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 3 dbid: 8FG name: ProQuest Technology Collection url: https://search.proquest.com/technologycollection1 sourceTypes: Aggregation Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 2191-219X |
EndPage | 70 |
ExternalDocumentID | oai_doaj_org_article_419a54cae201497fb0c6f20f21e962d4 10_1186_s13550_020_00646_w |
GroupedDBID | -A0 0R~ 3V. 40G 53G 5VS 7X7 8AO 8FE 8FG 8FI 8FJ AAFWJ AAJSJ AAKKN AAPBV AAYZJ ABDBF ABUWG ACACY ACGFS ACIHN ADBBV ADINQ AEAQA AENEX AFGXO AFKRA AFNRJ AFPKN AHBXF AHBYD AHMBA AHYZX ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIJS ARAPS BAPOH BCNDV BENPR BFQNJ BGLVJ BPHCQ BVXVI C24 C6C CCPQU EBS FYUFA GROUPED_DOAJ GX1 HCIFZ HMCUK HYE HZ~ IAO KQ8 M48 M~E OK1 P62 PIMPY PQQKQ PROAC RBZ RNS RPM RSV SMD SOJ U2A UKHRP AAYXX ABEEZ ACULB ALIPV CITATION EBLON PGMZT 7XB 8FK AZQEC DWQXO K9. PQEST PQUKI PRINS 7X8 5PM ITC |
ID | FETCH-LOGICAL-c584t-5b32e30c657b8220137d80a0dd8b2311c578090fd0d2c9c1e9100ce6868b5c313 |
IEDL.DBID | RPM |
ISSN | 2191-219X |
IngestDate | Thu Sep 05 15:46:37 EDT 2024 Tue Sep 17 21:10:09 EDT 2024 Fri Aug 16 21:50:34 EDT 2024 Fri Sep 13 03:46:29 EDT 2024 Fri Aug 23 03:07:56 EDT 2024 Sat Dec 16 12:03:45 EST 2023 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 1 |
Keywords | SERD F]-FDG SAR439859 Palbociclib Target engagement F]-FES [ Combination therapy Estrogen-positive breast cancer Positron emission tomography F]-FLT |
Language | English |
License | Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c584t-5b32e30c657b8220137d80a0dd8b2311c578090fd0d2c9c1e9100ce6868b5c313 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7324464/ |
PMID | 32601772 |
PQID | 2418450946 |
PQPubID | 2034773 |
PageCount | 1 |
ParticipantIDs | doaj_primary_oai_doaj_org_article_419a54cae201497fb0c6f20f21e962d4 pubmedcentral_primary_oai_pubmedcentral_nih_gov_7324464 proquest_miscellaneous_2419098251 proquest_journals_2418450946 crossref_primary_10_1186_s13550_020_00646_w springer_journals_10_1186_s13550_020_00646_w |
PublicationCentury | 2000 |
PublicationDate | 2020-06-29 |
PublicationDateYYYYMMDD | 2020-06-29 |
PublicationDate_xml | – month: 06 year: 2020 text: 2020-06-29 day: 29 |
PublicationDecade | 2020 |
PublicationPlace | Berlin/Heidelberg |
PublicationPlace_xml | – name: Berlin/Heidelberg – name: Heidelberg |
PublicationTitle | EJNMMI research |
PublicationTitleAbbrev | EJNMMI Res |
PublicationYear | 2020 |
Publisher | Springer Berlin Heidelberg Springer Nature B.V SpringerOpen |
Publisher_xml | – name: Springer Berlin Heidelberg – name: Springer Nature B.V – name: SpringerOpen |
References | McDonnell, Wardell, Norris (CR6) 2015; 58 El-Ahmad, Tabart, Halley, Certal, Thompson, Filoche-Rommé (CR7) 2019; 63 Heidari, Deng, Esfahani, Leece, Shoup, Vasdev (CR26) 2015; 21 Mortimer, Dehdashti, Siegel, Trinkaus, Katzenellenbogen, Welch (CR13) 2001; 19 Mankoff, Edmonds, Farwell, Pryma (CR33) 2016; 46 Kwapisz (CR20) 2017; 166 Xiong, Zhao, Gutgesell, Wang, Lee, Karumudi (CR8) 2017; 60 CR34 Liao, Clark, Schubert, Mankoff (CR11) 2016; 57 Kurland, Peterson, Lee, Schubert, Currin, Link (CR25) 2017; 23 Wardell, Ellis, Alley, Eisele, Van Arsdale, Dann (CR30) 2015; 21 Evangelista, Guarneri, Conte (CR12) 2016; 9 Wang, Ayres, Goldman, Dickler, Bardia, Mayer (CR19) 2017; 23 Clarke, Tyson, Dixon (CR3) 2015; 418 CR4 Toy, Shen, Won, Green, Sakr, Will (CR23) 2013; 45 Puhalla, Bhattacharya, Davidson (CR2) 2012; 6 Chae, Kim, Ahn, Kim, Yoon, Ahn (CR15) 2017; 58 Landmann, Farrugia, Zhu, Diego, Johnson, Soran (CR24) 2018; 150 Dunnwald, Rossing, Li (CR1) 2007; 9 CR9 van Kruchten, de Vries, Brown, de Vries, Glaudemans, Dierckx (CR16) 2013; 14 Murphy, Dickler (CR21) 2015; 20 He, Wang, Yang, Zhang, Zhang, Luo (CR27) 2016; 11 CR22 Ellis, Llombart-Cussac, Feltl, Dewar, Jasiówka, Hewson (CR5) 2015; 33 Pio, Park, Pietras, Hsueh, Satyamurthy, Pegram (CR29) 2006; 8 Rudin, Weissleder (CR32) 2003; 2 Linden, Peterson, Fowler (CR18) 2018; 13 Chalkidou, Landau, Odell, Cornelius (CR28) 2012; 48 Matthews, Rabiner, Passchier, Gunn (CR10) 2012; 73 Gong, Yang, Sun, Zhang, Zheng, Wang (CR17) 2017; 7 Elmi, Makvandi, Weng, Hou, Clark, Mach (CR31) 2019; 25 Linden, Stekhova, Link, Gralow, Livingston, Ellis (CR14) 2006; 24 A Landmann (646_CR24) 2018; 150 A Chalkidou (646_CR28) 2012; 48 L Evangelista (646_CR12) 2016; 9 D Kwapisz (646_CR20) 2017; 166 HM Linden (646_CR14) 2006; 24 DP McDonnell (646_CR6) 2015; 58 BF Kurland (646_CR25) 2017; 23 CG Murphy (646_CR21) 2015; 20 M Rudin (646_CR32) 2003; 2 SY Chae (646_CR15) 2017; 58 W Toy (646_CR23) 2013; 45 SE Wardell (646_CR30) 2015; 21 646_CR9 646_CR22 LK Dunnwald (646_CR1) 2007; 9 M van Kruchten (646_CR16) 2013; 14 C Gong (646_CR17) 2017; 7 BS Pio (646_CR29) 2006; 8 R Xiong (646_CR8) 2017; 60 JE Mortimer (646_CR13) 2001; 19 HM Linden (646_CR18) 2018; 13 P Heidari (646_CR26) 2015; 21 DA Mankoff (646_CR33) 2016; 46 Y El-Ahmad (646_CR7) 2019; 63 GJ Liao (646_CR11) 2016; 57 S Puhalla (646_CR2) 2012; 6 646_CR4 MJ Ellis (646_CR5) 2015; 33 S He (646_CR27) 2016; 11 A Elmi (646_CR31) 2019; 25 646_CR34 Y Wang (646_CR19) 2017; 23 R Clarke (646_CR3) 2015; 418 PM Matthews (646_CR10) 2012; 73 |
References_xml | – ident: CR22 – volume: 9 start-page: 244 year: 2016 end-page: 257 ident: CR12 article-title: 18F-Fluoroestradiol positron emission tomography in breast cancer patients: systematic review of the literature & meta-analysis publication-title: Curr Radiopharm doi: 10.2174/1874471009666161019144950 contributor: fullname: Conte – volume: 58 start-page: 563 year: 2017 end-page: 568 ident: CR15 article-title: A randomized feasibility study of [ F]-Fluoroestradiol PET to predict pathologic response to neoadjuvant therapy in estrogen receptor-rich postmenopausal breast cancer publication-title: J Nucl Med doi: 10.2967/jnumed.116.178368 contributor: fullname: Ahn – volume: 33 start-page: 3781 year: 2015 end-page: 3787 ident: CR5 article-title: Fulvestrant 500 mg versus anastrozole 1 mg for the FIRST-line treatment of advanced breast cancer: overall survival analysis from the phase II FIRST study publication-title: J Clin Oncol doi: 10.1200/JCO.2015.61.5831 contributor: fullname: Hewson – volume: 7 start-page: 6584 year: 2017 ident: CR17 article-title: A preliminary study of [ F]-FES PET/CT in predicting metastatic breast cancer in patients receiving docetaxel or fulvestrant with docetaxel publication-title: Sci Rep doi: 10.1038/s41598-017-06903-8 contributor: fullname: Wang – volume: 21 start-page: 1340 year: 2015 end-page: 1347 ident: CR26 article-title: Pharmacodynamic imaging guides dosing of a selective estrogen receptor degrader publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-14-1178 contributor: fullname: Vasdev – volume: 418 start-page: 220 year: 2015 end-page: 234 ident: CR3 article-title: Endocrine resistance in breast cancer – an overview and update publication-title: Mol Cell Endocrinol doi: 10.1016/j.mce.2015.09.035 contributor: fullname: Dixon – ident: CR4 – volume: 11 start-page: 1 year: 2016 end-page: 12 ident: CR27 article-title: Comparison of 18F-FES, 18F-FDG, and 18F-FMISO PET imaging probes for early prediction and monitoring of response to endocrine therapy in a mouse xenograft model of ER-positive breast cancer publication-title: PLoS One contributor: fullname: Luo – volume: 48 start-page: 3499 year: 2012 end-page: 3513 ident: CR28 article-title: O’Dohert.Y MJ, Marsden PK. Correlation between Ki-67 immunohistochemistry and 18F-fluorothymidine uptake in patients with cancer: a systematic review and meta-analysis publication-title: Eur J Cancer doi: 10.1016/j.ejca.2012.05.001 contributor: fullname: Cornelius – volume: 14 start-page: e465 year: 2013 end-page: ee75 ident: CR16 article-title: PET imaging of oestrogen receptors in patients with breast cancer publication-title: Lancet Oncol doi: 10.1016/S1470-2045(13)70292-4 contributor: fullname: Dierckx – volume: 19 start-page: 2797 year: 2001 end-page: 803 ident: CR13 article-title: Metabolic flare: indicator of hormone responsiveness in advanced breast cancer publication-title: J Clin Oncol. doi: 10.1200/JCO.2001.19.11.2797 contributor: fullname: Welch – volume: 9 start-page: R6 year: 2007 ident: CR1 article-title: Hormone receptor status, tumor characteristics, and prognosis: a prospective cohort of breast cancer patients publication-title: Breast Cancer Res doi: 10.1186/bcr1639 contributor: fullname: Li – volume: 57 start-page: 1269 year: 2016 end-page: 1275 ident: CR11 article-title: 18F-Fluoroestradiol PET: current status and potential future clinical applications publication-title: J Nucl Med doi: 10.2967/jnumed.116.175596 contributor: fullname: Mankoff – volume: 8 start-page: 36 year: 2006 end-page: 42 ident: CR29 article-title: Usefulness of 3′-[F-18]fluoro-3′-deoxythymidine with positron emission tomography in predicting breast cancer response to therapy publication-title: Mol Imaging Biol doi: 10.1007/s11307-005-0029-9 contributor: fullname: Pegram – volume: 2 start-page: 123 year: 2003 end-page: 131 ident: CR32 article-title: Molecular imaging in drug discovery and development publication-title: Nat Rev Drug Discov doi: 10.1038/nrd1007 contributor: fullname: Weissleder – volume: 23 start-page: 3053 year: 2017 end-page: 3060 ident: CR19 article-title: 18F-Fluoroestradiol PET/CT measurement of estrogen receptor suppression during a phase I trial of the novel estrogen receptor-targeted therapeutic GDC-0810: using an imaging biomarker to guide drug dosage in subsequent trials publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-16-2197 contributor: fullname: Mayer – volume: 63 start-page: 512 year: 2019 end-page: 528 ident: CR7 article-title: Discovery of 6-(2,4-Dichlorophenyl)-5-[4-[(3S)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7H-benzo[7]annulene-2-carboxylic acid (SAR439859), a potent and selective estrogen receptor degrader (SERD) for the treatment of estrogen receptor-positive breast cancer publication-title: J Med Chem doi: 10.1021/acs.jmedchem.9b01293 contributor: fullname: Filoche-Rommé – volume: 6 start-page: 222 year: 2012 end-page: 236 ident: CR2 article-title: Hormonal therapy in breast cancer: a model disease for the personalization of cancer care publication-title: Mol Oncol doi: 10.1016/j.molonc.2012.02.003 contributor: fullname: Davidson – volume: 58 start-page: 4883 year: 2015 end-page: 4887 ident: CR6 article-title: Oral selective estrogen receptor downregulators (SERDs) a breakthrough endocrine therapy for breast cancer publication-title: J Med Chem doi: 10.1021/acs.jmedchem.5b00760 contributor: fullname: Norris – volume: 60 start-page: 1325 year: 2017 end-page: 1342 ident: CR8 article-title: Novel selective estrogen receptor downregulators (SERDs) developed against treatment-resistant breast cancer publication-title: J Med Chem doi: 10.1021/acs.jmedchem.6b01355 contributor: fullname: Karumudi – volume: 46 start-page: 47 year: 2016 end-page: 56 ident: CR33 article-title: Development of companion diagnostics publication-title: Semin Nucl Med doi: 10.1053/j.semnuclmed.2015.09.002 contributor: fullname: Pryma – volume: 23 start-page: 407 year: 2017 end-page: 415 ident: CR25 article-title: Estrogen receptor binding (18F-FES PET) and glycolytic activity (18F-FDG PET) predict progression-free survival on endocrine therapy in patients with ER+ breast cancer publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-16-0362 contributor: fullname: Link – volume: 13 start-page: 415 year: 2018 end-page: 422 ident: CR18 article-title: Clinical potential of estrogen and progesterone receptor imaging publication-title: PET Clin doi: 10.1016/j.cpet.2018.02.005 contributor: fullname: Fowler – volume: 25 start-page: 3063 year: 2019 end-page: 3073 ident: CR31 article-title: Cell-proliferation imaging for monitoring response to CDK4/6 inhibition combined with endocrine-therapy in breast cancer: comparison of [18F]FLT and [18F]ISO-1 PET/CT publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-18-2769 contributor: fullname: Mach – volume: 45 start-page: 1439 year: 2013 end-page: 1445 ident: CR23 article-title: ESR1 ligand-binding domain mutations in hormone-resistant breast cancer publication-title: Nat Genet doi: 10.1038/ng.2822 contributor: fullname: Will – volume: 73 start-page: 175 year: 2012 end-page: 186 ident: CR10 article-title: Positron emission tomography molecular imaging for drug development publication-title: Br J Clin Pharmacol doi: 10.1111/j.1365-2125.2011.04085.x contributor: fullname: Gunn – volume: 20 start-page: 483 year: 2015 end-page: 490 ident: CR21 article-title: The role of CDK4/6 inhibition in breast cancer publication-title: Oncologist doi: 10.1634/theoncologist.2014-0443 contributor: fullname: Dickler – volume: 21 start-page: 5121 year: 2015 end-page: 5130 ident: CR30 article-title: Efficacy of SERD/SERM hybrid-CDK4/6 inhibitor combinations in models of endocrine therapy-resistant breast cancer publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-15-0360 contributor: fullname: Dann – volume: 150 start-page: 34 year: 2018 end-page: 42 ident: CR24 article-title: Low estrogen receptor (ER)-positive breast cancer and neoadjuvant systemic chemotherapy: is response similar to typical ER-positive or ER-negative disease? publication-title: Am J Clin Pathol doi: 10.1093/ajcp/aqy028 contributor: fullname: Soran – ident: CR9 – ident: CR34 – volume: 24 start-page: 2793 year: 2006 end-page: 2799 ident: CR14 article-title: Quantitative fluoroestradiol positron emission tomography imaging predicts response to endocrine treatment in breast cancer publication-title: J Clin Oncol doi: 10.1200/JCO.2005.04.3810 contributor: fullname: Ellis – volume: 166 start-page: 41 year: 2017 end-page: 54 ident: CR20 article-title: Cyclin-dependent kinase 4/6 inhibitors in breast cancer: palbociclib, ribociclib, and abemaciclib publication-title: Breast Cancer Res Treat doi: 10.1007/s10549-017-4385-3 contributor: fullname: Kwapisz – ident: 646_CR4 doi: 10.1016/S1470-2045(15)00613-0 – volume: 60 start-page: 1325 year: 2017 ident: 646_CR8 publication-title: J Med Chem doi: 10.1021/acs.jmedchem.6b01355 contributor: fullname: R Xiong – volume: 45 start-page: 1439 year: 2013 ident: 646_CR23 publication-title: Nat Genet doi: 10.1038/ng.2822 contributor: fullname: W Toy – volume: 46 start-page: 47 year: 2016 ident: 646_CR33 publication-title: Semin Nucl Med doi: 10.1053/j.semnuclmed.2015.09.002 contributor: fullname: DA Mankoff – volume: 48 start-page: 3499 year: 2012 ident: 646_CR28 publication-title: Eur J Cancer doi: 10.1016/j.ejca.2012.05.001 contributor: fullname: A Chalkidou – volume: 166 start-page: 41 year: 2017 ident: 646_CR20 publication-title: Breast Cancer Res Treat doi: 10.1007/s10549-017-4385-3 contributor: fullname: D Kwapisz – volume: 150 start-page: 34 year: 2018 ident: 646_CR24 publication-title: Am J Clin Pathol doi: 10.1093/ajcp/aqy028 contributor: fullname: A Landmann – volume: 14 start-page: e465 year: 2013 ident: 646_CR16 publication-title: Lancet Oncol doi: 10.1016/S1470-2045(13)70292-4 contributor: fullname: M van Kruchten – volume: 9 start-page: R6 year: 2007 ident: 646_CR1 publication-title: Breast Cancer Res doi: 10.1186/bcr1639 contributor: fullname: LK Dunnwald – ident: 646_CR9 doi: 10.1158/1538-7445.SABCS16-P3-04-05 – volume: 73 start-page: 175 year: 2012 ident: 646_CR10 publication-title: Br J Clin Pharmacol doi: 10.1111/j.1365-2125.2011.04085.x contributor: fullname: PM Matthews – volume: 63 start-page: 512 year: 2019 ident: 646_CR7 publication-title: J Med Chem doi: 10.1021/acs.jmedchem.9b01293 contributor: fullname: Y El-Ahmad – volume: 57 start-page: 1269 year: 2016 ident: 646_CR11 publication-title: J Nucl Med doi: 10.2967/jnumed.116.175596 contributor: fullname: GJ Liao – volume: 7 start-page: 6584 year: 2017 ident: 646_CR17 publication-title: Sci Rep doi: 10.1038/s41598-017-06903-8 contributor: fullname: C Gong – volume: 2 start-page: 123 year: 2003 ident: 646_CR32 publication-title: Nat Rev Drug Discov doi: 10.1038/nrd1007 contributor: fullname: M Rudin – volume: 24 start-page: 2793 year: 2006 ident: 646_CR14 publication-title: J Clin Oncol doi: 10.1200/JCO.2005.04.3810 contributor: fullname: HM Linden – volume: 58 start-page: 4883 year: 2015 ident: 646_CR6 publication-title: J Med Chem doi: 10.1021/acs.jmedchem.5b00760 contributor: fullname: DP McDonnell – volume: 21 start-page: 5121 year: 2015 ident: 646_CR30 publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-15-0360 contributor: fullname: SE Wardell – volume: 25 start-page: 3063 year: 2019 ident: 646_CR31 publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-18-2769 contributor: fullname: A Elmi – volume: 19 start-page: 2797 year: 2001 ident: 646_CR13 publication-title: J Clin Oncol. doi: 10.1200/JCO.2001.19.11.2797 contributor: fullname: JE Mortimer – volume: 23 start-page: 3053 year: 2017 ident: 646_CR19 publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-16-2197 contributor: fullname: Y Wang – volume: 6 start-page: 222 year: 2012 ident: 646_CR2 publication-title: Mol Oncol doi: 10.1016/j.molonc.2012.02.003 contributor: fullname: S Puhalla – volume: 58 start-page: 563 year: 2017 ident: 646_CR15 publication-title: J Nucl Med doi: 10.2967/jnumed.116.178368 contributor: fullname: SY Chae – volume: 11 start-page: 1 year: 2016 ident: 646_CR27 publication-title: PLoS One contributor: fullname: S He – volume: 33 start-page: 3781 year: 2015 ident: 646_CR5 publication-title: J Clin Oncol doi: 10.1200/JCO.2015.61.5831 contributor: fullname: MJ Ellis – volume: 23 start-page: 407 year: 2017 ident: 646_CR25 publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-16-0362 contributor: fullname: BF Kurland – volume: 8 start-page: 36 year: 2006 ident: 646_CR29 publication-title: Mol Imaging Biol doi: 10.1007/s11307-005-0029-9 contributor: fullname: BS Pio – volume: 13 start-page: 415 year: 2018 ident: 646_CR18 publication-title: PET Clin doi: 10.1016/j.cpet.2018.02.005 contributor: fullname: HM Linden – ident: 646_CR34 doi: 10.2967/jnumed.115.157974 – volume: 20 start-page: 483 year: 2015 ident: 646_CR21 publication-title: Oncologist doi: 10.1634/theoncologist.2014-0443 contributor: fullname: CG Murphy – volume: 418 start-page: 220 year: 2015 ident: 646_CR3 publication-title: Mol Cell Endocrinol doi: 10.1016/j.mce.2015.09.035 contributor: fullname: R Clarke – volume: 21 start-page: 1340 year: 2015 ident: 646_CR26 publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-14-1178 contributor: fullname: P Heidari – volume: 9 start-page: 244 year: 2016 ident: 646_CR12 publication-title: Curr Radiopharm doi: 10.2174/1874471009666161019144950 contributor: fullname: L Evangelista – ident: 646_CR22 doi: 10.1158/1538-7445.AM2018-943 |
SSID | ssj0000515938 |
Score | 2.2552447 |
Snippet | Purpose
Preclinical in vivo nuclear imaging of mice offers an enabling perspective to evaluate drug efficacy at optimal dose and schedule. In this study, we... Abstract Purpose Preclinical in vivo nuclear imaging of mice offers an enabling perspective to evaluate drug efficacy at optimal dose and schedule. In this... PurposePreclinical in vivo nuclear imaging of mice offers an enabling perspective to evaluate drug efficacy at optimal dose and schedule. In this study, we... PURPOSEPreclinical in vivo nuclear imaging of mice offers an enabling perspective to evaluate drug efficacy at optimal dose and schedule. In this study, we... Abstract Purpose Preclinical in vivo nuclear imaging of mice offers an enabling perspective to evaluate drug efficacy at optimal dose and schedule. In this... |
SourceID | doaj pubmedcentral proquest crossref springer |
SourceType | Open Website Open Access Repository Aggregation Database Publisher |
StartPage | 70 |
SubjectTerms | Anticancer properties Biomarkers Breast cancer Cardiac Imaging Combination therapy Correlation analysis Degradation Estrogen-positive breast cancer Estrogens Evaluation Fluorine isotopes Imaging Medical imaging Medicine Medicine & Public Health Nuclear Medicine Occupancy Oncology Original Research Orthopedics Palbociclib Positron emission Radiology Receptors SAR439859 Schedules SERD Synergistic effect Target engagement Tomography |
SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1NaxYxEA7Sg3gRP_HVKiN4s6HZj2STYxVLEepBLfQW8jFbC7pb9n1r6T_z5znJ7tZ3C-LF62Yhyc5M5pnNzDOMvalj5aNRkQcMkdeEELjxquBGOq80yqDKVDt8_EkdndQfT-XpVquvlBM20gOPH26_LoyTdXBYJjDftF4E1ZaiLQs0qowjE2ght4KpidVbmkrPVTJa7a8L8qyCp2gpuWHFrxaeKBP2L1Dm7RzJWxel2f8cPmD3J-AIB-OCH7I72D1id4-nq_HH7Ff2Ot-nf3uwHllnryEltp_BnDcIXeIvdgOc_8jtiSCV36cMnWENmx4m7m-EMUEcsDubkmPAdREwsSHDVskWYGKgcOEa-ha-HHwm3KGl2QMHXf8TaRW5yw4dqECbHXpSVqATFi8o0IeYaCoiDk_YyeGHr--P-NSWgQdCKxsufVViRWKQjSd4kTgLoxZOxKg9ocUi0CEgjGijiGUwgeRUCBFQaaW9DFVRPWU7Xd_hMwaOEJdvRTTYBgr0gm6qAkPbuFYLHZxbsbeziOzFyL5hc9SilR0FakmgNgvUXq3YuyTFmzcTc3Z-QPpkJ32y_9KnFduddcBO5ry2BHN0nagG1Yq9vhkmQ0y3K67D_jK_Y4RJlcAr1ix0Z7Gg5Uh3_i1TejeEa2tFk-_NWvZn8r9v-Pn_2PALdq_MVqF4aXbZzma4xJcEtDb-Vbap30IZKUM priority: 102 providerName: Directory of Open Access Journals – databaseName: ProQuest Technology Collection dbid: 8FG link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9QwELZKkRAXxFMsFDRI3Ki1zsuxT6gglhVSOQCVeov8ylKpJEs2peo_4-cx4022pBJc40i2NeOZb-yZbxh7nfvMei09d8F5niNC4NrKhOvCWKlC4WRKtcPHn-XyJP90WpzuseVYC0NplaNNjIbat47uyOfoaVRObG9ybizdArh-_nb9k1P_KHpnHZpp3GK3E-LEo5rxxcfdbQt1MtGZGqtmlJxvEvS0glP0RG5Z8suJZ4oE_hPUeTNn8sbDafRHi_vs3gAk4Wgr-QdsLzQP2Z3j4an8EfsdvdD5cNcHmy0L7RVQovsKxjxCaIjP2HRw9iO2KwIqx6eMnW4DfQsDF3iAbcI4hGY1JMuAaTwEYkeGv0q4IBAjhXFX0Nbw9egL4hBV6EMw0LS_Aq4idt1BAwu42a5F5QW0uGGNgT94oq3woXvMThYfvr1f8qFNA3eIXnpe2CwNmXCyKC3CDeIw9EoY4b2yiB4Th0ZBaFF74VOnXRIQoQgXpJLKFi5Lsidsv2mb8JSBQQRma-F1qB0Gfk6VWRJcXZpaCeWMmbE3o4iq9ZaNo4pRjJLVVqAVCrSKAq0uZ-wdSXH3JzFpxw9tt6qGg1nliTZF7kxIKVgsa4sbqVNRp7hOmfp8xg5GHaiG472prpVxxl7thvFg0muLaUJ7Ef_RQlNl8IyVE92ZLGg60px9jxTfJeLcXOLkh6OWXU_-7w0_-_9an7O7adR3yVN9wPb77iK8QEjV25fxtPwBD3Uk3g priority: 102 providerName: ProQuest – databaseName: Scholars Portal Journals: Open Access(OpenAccess) dbid: M48 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Nb9QwELVKkRAXVL7EQkGDxI0aHMdx7ANCBVFVSMsBWKm3yLGdpVJJSnZL2X_Wn8fYcQqpCtc4UezMjOdNPPOGkBfC5bXT0lHrraMCEQLVtcyoLkwtlS-s5KF2eP5JHi7Ex6PiaIuM7Y7SB1xdG9qFflKL_uTVrx-bt2jwb6LBK_l6laHTZDQEQsHDSnp-g9zkIhdB4-cJ7ieu70LnaqydufbRiX-KNP4T7Hk1c_LK8Wn0Sgc75E6Ck7A_yP8u2fLtPXJrng7M75OL6ItO0h8_WA1ctBsI6e5LGLMJoQ2sxqaH4--xaRGEovyQt9OvYN1BYgT3MKSNg2-XKWUGTOvAB45k-KuQC3zgpTB2A10DX_Y_IxpRhd4DA2330-MsYu8d3GYBF9t3qMKA-64_xfAfXCCvcL5_QBYHH76-P6SpWQO1iGHWtKhz7nNmZVHWCDoCk6FTzDDnVI0YMrO4NTDNGscct9pmHnEKs14qqerC5ln-kGy3XesfETCIw-qGOe0bi-GfVWWeeduUplFMWWNm5OUooup04OSoYiyjZDUItEKBVlGg1fmMvAtSvLwz8GnHC12_rJJ5ViLTphDWeB5CxrKpcSENZw3HeUruxIzsjjpQjTpaIfhRIhAQyhl5fjmM5hnOXEzru7N4j2Y61AfPSDnRncmEpiPt8bdI9F0i2hUSX743atmfl_97wY__P9cn5DaP-i4p17tke92f-acIrNb1s2gtvwE4NCSL priority: 102 providerName: Scholars Portal – databaseName: Springer_OA刊 dbid: C6C link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1baxUxEA5aQXwRr7haZQTfbDB7yyaP9WApQn1QC30LuW0t6G7Zc2rpP_PnOZPdPXaLPvi6yZKEmcl8k8x8YexNFUoXtAzcRx94hQiBaydzrmvrpIq1lwXVDh99kofH1ceT-mSiyaFamOv397mS79Y5OkTBKcgh7yn55W12p0aYQka4kqvteQq9VaJLNdfF_PXXhe9JFP0LXHkzK_LG1WjyOAcP2P0JKsL-KNuH7FbsHrG7R9Nl-GP2K_mZ79NpHqxHntkroFT2U5gzBaEjxmI7wNmP9CARUME95eQMa9j0MLF9RxhTwiF2p1M6DNguQCT-Y7hWpAWROCesv4K-hS_7nxFpqFrvgYWu_xlxFuldHdxCARc79KiegHtqPMfQHgIRU4Q4PGHHBx--rg759BAD94hPNrx2ZRFL4WXdOAQUxFIYlLAiBOUQH-YezV5o0QYRCq99HhGDCB-lksrVvszLp2yn67v4jIFFjOVaEXRsPYZ2XjVlHn3b2FYJ5a3N2NtZROZ85NswKU5R0owCNShQkwRqLjP2nqS47Ulc2ekDqpCZTM9UubZ15W0sKBxsWocLaQvRFjhPWYQqY7uzDpjJgNcGgY2qiFxQZuz1thlNj-5TbBf7i9RHC021vxlrFrqzmNCypTv7lki8G0SylcTB92Yt-zP4vxf8_P-6v2D3iqT_khd6l-1shov4EkHUxr1K1vMbgZcaaw priority: 102 providerName: Springer Nature |
Title | Translational strategy using multiple nuclear imaging biomarkers to evaluate target engagement and early therapeutic efficacy of SAR439859, a novel selective estrogen receptor degrader |
URI | https://link.springer.com/article/10.1186/s13550-020-00646-w https://www.proquest.com/docview/2418450946/abstract/ https://search.proquest.com/docview/2419098251 https://pubmed.ncbi.nlm.nih.gov/PMC7324464 https://doaj.org/article/419a54cae201497fb0c6f20f21e962d4 |
Volume | 10 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3da9swEBdNB6UvY58sWxdusLfVjSzLsvSYhmZlkFK6BfJmZEnuAo0dnHSl_9n-vJ0Uu2sKe9nL4S-wxJ10v5PufiLkM7dJYZWwkXHGRhwRQqQKEUcq1YWQLjWC-drh6YU4n_Fv83S-R9KuFiYk7ZticVLdLE-qxc-QW7lammGXJza8nI4zRAFc8GGP9LIkeRSit4TeqUpkVyAjxXAdo1OlkQ-UvAcW0d0hOUg8l1aWsR1_FGj7d7Dm00zJJ9ulwQtNXpDnLXyE0baZL8meq16Rg2m7Qf6a_A6-56Zd4YP1lnv2Hnx6-zV02YNQeRZj3cBiGQ4pAl-E7_N0mjVsamgZwB1s08TBVddtigzoyoLznMjwqHALnOeh0OYe6hK-j64QfchUHYOGqv7lsBXhrB2cVgE729RosoDzrFthuA_Wk1VY17whs8nZj_F51B7OEBnELJsoLRLmEmpEmhUIMjxzoZVUU2tlgZgxNjgVUEVLSy0zysQOcQk1Tkghi9QkcfKW7Fd15d4R0Ii7ipJa5UqD4Z6RWRI7U2a6lFQarfvkS6eifLXl4MhD7CJFvtVtjrrNg27zuz459Vp8-NLzZ4cHdXOdt1aU81jplBvtmA8Rs7LAjpSMlgzbKZjlfXLU2UDeDup1jmBHck84KPrk08NrHI5-j0VXrr4N3yiqfD1wn2Q7trPToN03aOeB2Lu16z457qzs78__3eH3__2jD-SQhVEhIqaOyP6muXUfEWNtigHpcfoVZTbPUMoJXj87Pbu4vMK7MeNeivEgrGCgnHI5CKMQ5YyN_gA0zTKg |
link.rule.ids | 230,315,733,786,790,870,891,2115,2236,12083,12792,21416,24346,27957,27958,31754,31755,33408,33409,33779,33780,40936,41154,41155,41558,42005,42223,42224,42627,43345,43635,43840,51611,52130,52268,52269,53827,53829,74102,74392,74659 |
linkProvider | National Library of Medicine |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9QwELagSMAF8RRbCgwSN2rVeTn2CRVEtUC3B2ilvUWO7WwrQbLNbqn6z_h5zHidLVsJrnEk25rxzDf2zDeMvc1dVjstHbfeOp4jQuC6lgnXhaml8oWVKdUOT47k-CT_Mi2m8cJtEdMqB5sYDLXrLN2R76GnUTmxvcn383NOXaPodTW20LjN7uRZllNKXzkt13cs1L9EZ2qolVFyb5GgfxWcYiZyxpJfbvijQNu_gTVvZkreeC4NXujgIXsQ4SPsr-T9iN3y7WN2dxIfyJ-w38H3_Ig3fLBYcc9eAaW3z2DIHoSWWIxND2c_Q5MioCJ8ytPpF7DsIDKAe1iliYNvZzFFBkzrwBMnMvxVuAWeeCiMvYKuge_73xB9qELvgoG2--VxFaHXDppVwM32HaosoJ31cwz3wRFZhfP9U3Zy8On445jH5gzcImZZ8qLOUp8JK4uyRpBBzIVOCSOcUzVixsSiKRBaNE641GqbeMQlwnqppKoLmyXZM7bVdq1_zsAg7qob4bRvLIZ7VpVZ4m1TmkYJZY0ZsXeDiKr5ioOjCrGLktVKoBUKtAoCrS5H7ANJcf0n8WeHD10_q-JxrPJEmyK3xqcUIpZNjRtpUtGkuE6ZunzEdgYdqOKhXlTXKjhib9bDeBzpjcW0vrsI_2ihqR54xMoN3dlY0OZIe3YaiL1LRLe5xMl3By27nvzfG97-_1pfs3vj48lhdfj56OsLdj8Nui95qnfY1rK_8C8RVC3rV-Hk_AEzuyQM |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9QwELaglSouFU8RKDBI3Ki1zsuxT6iFrsqjq6pQqTfLsZ2lEiTb7Jaq_4yfx9jrbNlKcE0ixda8vrFnviHkTWHz2kpuqXHG0gIRApU1T6ksdc2FKw3PfO_w0YQfnhafzsqzWP80j2WVg08Mjtp2xp-RjzDSiMKzvfFRE8sijj-M380uqJ8g5W9a4ziNu2SzKniJGr65fzA5PlmduPhpJjIXQ-eM4KN5itGWUZ9B-dDM6dVadAok_mvI83bd5K3L0xCTxvfJdgSTsLeU_gNyx7UPydZRvC5_RH6HSPQjnvfBfMlEew2-2H0KQy0htJ7TWPdw_jOMLALfku-rdvo5LDqIfOAOlkXj4NppLJgB3VpwniEZ_mrjAudZKbS5hq6Br3sniEVEKXdBQ9v9criKMHkHnSzgZvsOFRjQ67oZJv9gPXWFdf1jcjo--Pb-kMZRDdQgglnQss4zlzPDy6pGyOF5DK1gmlkrakSQqUHHwCRrLLOZkSZ1iFKYcVxwUZcmT_MnZKPtWveUgEYUVjfMStcYTP6MqPLUmabSjWDCaJ2Qt4OI1GzJyKFCJiO4WgpUoUBVEKi6Ssi-l-LqS8-mHR50_VRF41RFKnVZGO0ynzBWTY0baTLWZLhOntkiITuDDqho4nN1o5AJeb16jcbpb1x067rL8I1k0ncHJ6Ra0521Ba2_ac-_B5rvCrFuwfHnu4OW3fz83xt-9v-1viJbaDbqy8fJ5-fkXhZUn9NM7pCNRX_pXiDCWtQvo-n8Acl5Ka8 |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Translational+strategy+using+multiple+nuclear+imaging+biomarkers+to+evaluate+target+engagement+and+early+therapeutic+efficacy+of+SAR439859%2C+a+novel+selective+estrogen+receptor+degrader&rft.jtitle=EJNMMI+research&rft.au=Besret+Laurent&rft.au=d%E2%80%99Heilly+S%C3%A9bastien&rft.au=Aubert%2C+Cathy&rft.au=Bluet+Guillaume&rft.date=2020-06-29&rft.pub=Springer+Nature+B.V&rft.eissn=2191-219X&rft.volume=10&rft.issue=1&rft_id=info:doi/10.1186%2Fs13550-020-00646-w&rft.externalDBID=HAS_PDF_LINK |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2191-219X&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2191-219X&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2191-219X&client=summon |